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Abstract
The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in
cancer outcome continue to the present day. However, the wealth of data suggesting that AA may be highly
beneficial in addressing cancer-associated inflammation, particularly progression to systemic inflammatory response
syndrome (SIRS) and multi organ failure (MOF), has been largely overlooked. Patients with advanced cancer are
generally deficient in AA. Once these patients develop septic symptoms, a further decrease in ascorbic acid levels
occurs. Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers;
b) protection from sepsis in animal models; and c) direct antineoplastic effects, we propose the use of ascorbate as
an adjuvant to existing modalities in the treatment and prevention of cancer-associated sepsis.
Personal Perspective
Having worked in the area of cancer research for over a
decade, the major focus of one of the authors’ investiga-
tions has been to develop therapeutic solutions by using
siRNA to directly inhibit growth of tumors [1], and to
stimulate tumor immunity using antigen-specific
vaccines [2-4] or unorthodox immune-modulatory
approaches [5-9]. Not until the author’s mother passed
away from leukemia did he realize that, while many
options have been developed in the treatment of can-
cers, relatively little can be performed at end-of-life.
While life support technologies have significantly
increased life span, the quality of life at end stages can
be devastatingly poor. The author (whose training was
in the basic research space) was surprised to realize
that, for the majority of cancers, the patient is literally
“waiting to die” while on various supportive measures.
This led to the realization that there is a major need
for supportive steps that: increase the quality of life, “do
no harm”, and hold out the possibility (however slim) of
restoring some measure of lost life functions back to
patients. One intervention that caught the attention of
the author while at his mother’s bedside was the prac-
tice of intravenous ascorbic acid (IV AA) administration
[10,11]. That specific intervention was supported by a
report in the literature that intravenous administration
of AA (10g twice and 4 g daily orally for one week)sig-
nificantly increased the quality of life in end stage
patients [12]. Could such an easy-to-implement therapy
actually be of benefit to patients facing the same chal-
lenges of the deceased mother of the author?
When the author discussed this option with others, it
became evident that the value of i.v. AA in cancer treat-
ment is controversial. In the 1970 s work by Cameron
and Pauling demonstrated an approximate 4-fold survi-
val increase in terminal cancer patients administered
AA by i.v. and oral routes, compared to historical con-
trols [13,14], a finding that was also observed in the
results of a trial published by Murata et al. [15]. Subse-
quent trials that did not use historical controls but had
a double-blind placebo-controlled design failed to find
benefit [16,17]. The controversy has continued with
recent reports that oral AA administration, which was
used in the trials that failed to demonstrate benefit, fails
to increase plasma concentrations to a level estimated to
be sufficient to induce tumor cytotoxicity [18-24].
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medicine” practitioners in the USA (11,233 patients
treated in 2006 and 8876 patients in 2008) [25],
although the basis for this practice has not been adopted
into mainstream medicine. It is our belief that, in the
practice of medicine, opinion should not hold greater
weight than evidence - either a treatment has beneficial
effects or it does not, and it is that consideration that
must drive practice. We therefore sought, not to address
the controversial area of whether AA shrinks tumors
(which is currently being addressed in ongoing FDA
approved trials [26-31]), but instead in an area that we
feel has been highly under-explored: that is, suppression
of inflammation in the cancer patient. In the context of
cancer, inflammation may be seen as a continuum of
possible degrees of severity ranging from low level,
chronic inflammatory response to acute, highly severe
inflammation. At the chronic end, low grade inflamma-
tion causes a variety of pathologies to the patient, per-
haps most profound of which is cachexia [32-35], but
also other effects such as poor post-surgical outcomes
[36,37]. At the other end of the spectrum is the acute
inflammation observed in the systemic inflammatory
response syndrome (SIRS), a major cause of death of
cancer patients and especially patients with hematologi-
cal malignancies [38-40]. While we focus in this paper
on SIRS and cancer, some of the concepts discussed are
also applicable to chronic inflammatory conditions.
What is SIRS?
According to the accepted definition, Systemic Inflam-
matory Response Syndrome (SIRS) is a term characteriz-
ing an inflammatory syndrome caused by infectious or
traumatic causes in which patients exhibit at least 2 of
the following criteria: 1) Body temperature less than 36°
C or greater than 38°C; 2) Heart rate greater than 90
beats per minute; 3)Tachypnea, with greater than 20
breaths per minute; or, an arterial partial pressure of
carbon dioxide less than 4.3 kPa (32 mmHg: 4) White
blood cell count less than 4000 cells/mm
3 (4 × 109
cells/L) or greater than 12,000 cells/mm
3 (12 × 109
cells/L); or the presence of greater than 10% immature
neutrophils (band forms) [41]. SIRS is different than
sepsis in that in sepsis an active infection is found [42].
T h e s ep a t i e n t sm a yp r o g r e s st oa c u t ek i d n e yo rl u n g
failure, shock, and multiple organ dysfunction syndrome.
The term septic shock refers to conditions in which the
patient has a systolic blood pressure of less than 90
mmHg despite sufficient fluid resuscitation and adminis-
tration of vasopressors/inotropes.
Predominant events in the progression to SIRS and
subsequently to MOF include: a) systemic activation of
inflammatory responses [43]; b) endothelial activation
and initiation of the clotting cascade, associated with
consumption of anticoagulants and fibrinolytic factors
[44]; c) complement activation [45]; and d) organ failure
and death. These pathological events appear to be
related to each other, for example, it is known that com-
plement activation stimulates the pro-coagulant state
[46]. In the cancer patient SIRS may be initiated by sev-
eral factors. Numerous patients receive immune sup-
pressive chemo/radiotherapies that promote
opportunistic infections [47,48]. Additionally, given that
approximately 40-70% of patients are cachectic, the low
grade inflammation causing the cachexia could augment
effects of additional bacterial/injury-induced inflamma-
tory cascades [49]. Finally, tumors themselves, and
through interaction with host factors, have been demon-
strated to generate systemically-acting inflammatory
mediators such as IL-1, IL-6, and TNF-alpha that may
predispose to SIRS [50,51].
Current SIRS treatments SIRS are primarily suppor-
tive. To date, the only drug to have elicited an effect on
SIRS in Phase III double-blind, placebo-controlled trials
has been Xigris (activated protein C (APC)) [52], which
exerts its effects by activating endothelial cell-protecting
mechanisms mediating protection against apoptosis, sti-
mulation of barrier function through the angiopoietin/
Tie-2 axis, and by reducing local clotting [53-55]. The
basis of approval for Xigris has been questioned by
some [56] and, additionally, it is often counter-indicated
in oncology-associated sepsis (especially leukemias
where bleeding is an issue of great concern). In fact, in
the Phase III trials of Xigris, hematopoietic transplant
patients were excluded [57]. Thus there is a great need
for progress in the area of SIRS treatment and adjuvant
approaches for agents such as Xigris.
Endothelial Dysfunction of SIRS
One of the main causes of death related to SIRS is dys-
function of the microcirculatory system, which in the
most advanced stages is manifested as disseminated
intravascular coagulation (DIC) [44]. Inflammatory med-
iators associated with SIRS, whether endotoxin or
injury-related signals such as TLR agonists or HMGB-1,
are all capable of activating endothelium systemically
[58,59]. Under physiological conditions, the endothelial
response to such mediators is local and provides a use-
ful mechanism for sequestering an infection and allow-
ing immune attack. In SIRS, the fact that the response is
systemic causes disastrous consequences includingorgan
failure. The characteristics of this endothelial response
include: a) upregulation of tissue factor (TF) [60,61] and
suppression of endothelial inhibitors of coagulation such
as protein C and the antithrombin system causing a
pro-coagulant state [62]; b) increased expression of
adhesion molecules which elicit, in turn, neutrophil
extravasation [63]; c) decreased fibrinolytic capacity
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responsiveness to vaso-dilators and vasoconstrictors
[67,68]. Excellent detailed reviews of molecular signals
associated with SIRS-induced endothelial dysfunction
have been published [69-77] and one of the key factors
implicated has been NF-kB [78]. Nuclear translocation
of NF-kB is associated with endothelial upregulation of
pro-thrombotic molecules and suppressed fibrinolysis
[79-81]. In an elegant study, Song et al. inhibited NF-kB
selectively in the endothelium by creation of transgenic
mice transgenic expressing exogenous i-kappa B (the
NF-kB inhibitor) specifically in the vasculature. In con-
trast to wild-type animals, the endothelial cells of these
transgenic mice experienced substantially reduced
expression of tissue factor while retaining expression of
endothelial protein C receptor and thrombomodulin
subsequent to endotoxin challenge. Furthermore,
expression of NF-B was associated with generation of
TNF-alpha as a result of TACE activity [82].
It is interesting that the beneficial effects of Xigris in
SIRS appear to be associated with its ability to prevent
the endothelial dysfunction [83] associated with suppres-
sion of proinflammatory chemokines [84], prevention of
endothelial cell apoptosis [85], and increased endothelial
fibrinolytic activity [86,87]. Some of the protective activ-
ities of Xigris have been ascribed to its ability to sup-
press NF-kB activation in endothelial cells [88,89].
Ascorbic Acid Effects on Endothelium
Several clinical studies have supported the possibility
that AA mediates a beneficial effect on endothelial cells,
especially in the context of chronic stress. Heitzer et al.
[90] examined acetylcholine-evoked endothelium-depen-
dent vaso-responsiveness in 10 chronic smokers and 10
healthy volunteers. While responsiveness was suppressed
in smokers, administration of intra-arterial ascorbate
was capable of augmenting reactivity: an augmentation
evident only in the smokers. Endothelial stress induced
in 17 healthy volunteers by administration of L-methio-
nine led to decreased responsiveness to hyperemic flow
and increased homocysteine levels. Oral AA (1 g/day)
restored endothelial responsiveness [91]. Restoration of
endothelial responsiveness by AA has also been reported
in patients with insulin-dependent [92] and independent
diabetes [93], as well as chronic hypertension [94]. In
these studies AA was administered intraarterially or
intravenously, and the authors proposed the mechanism
of action to be increased nitric oxide (NO) as a result of
AA protecting it from degradation by reactive oxygen
species (ROS).
A closer look at the literature suggests that there are
several general mechanisms by which AA may exert
endothelial protective properties. The importance of
basal production of NO in endothelial function comes
from its role as a vasodilator, and an inhibitor of platelet
aggregation [95,96]. High concentrations of NO are
pathological in SIRS due to induction of vascular leak-
age [97]. However, lack of NO is also pathological
because it causes loss of microvascular circulation and
endothelial responsiveness [98,99]. Although there are
exceptions, the general concept is that inducible nitric
oxide synthase (iNOS) and neuronal nitric oxide
synthase (nNOS) are associated with sepsis-induced
pathologies, whereas eNOS is associated with protective
benefits [100]. It is important to note that, while iNOS
expression occurs in almost all major cells of the body
in the context of inflammation, eNOS is constitutively
expressed by the endothelium. AA administration
decreases iNOS in the context of inflammation
[101,102], but appears to increase eNOS [103]. Thus,
AA appears to increase local NO concentrations
through: a) prevention of ROS-mediated NO inactiva-
tion [104,105]; b) increased activity of endothelial-speci-
fic nitric oxide synthase (eNOS) [106], possibly
mediated by augmenting bioavailability of tetrahydro-
biopterin [107-112], a co-factor of eNOS [113]; and c)
induction of NO release from plasma-bound S-nitro-
sothiols [103].
In addition to deregulation of NO, numerous other
endothelial changes occur during SIRS, including
endothelial cell apoptosis, upregulation of adhesion
molecules, and the procoagulant state [114]. AA has
been reported to be active in modulating each of these
factors. Rossig et al.r e p o r t e dt h a tin vitro administra-
tion of AA led to reduction of TNF-alpha induced
endothelial cell apoptosis [109]. The effect was mediated
in part through suppression of the mitochondria-
initiated apoptotic pathway as evidenced by reduced cas-
pase-9 activation and cytochrome c release. To extend
their study into the clinical realm, the investigators pro-
spectively randomized 34 patients with NYHA class III
and IV heart failure to receive AA or placebo treatment.
AA treatment (2.5 g administered intravenously and 3
days of 4 g per day oral AA) Resulted in reduction in
circulating apoptotic endothelial cells in the treated but
not placebo control group [115]. Various mechanisms
for inhibition of endothelial cell apoptosis by AA have
been proposed including upregulation of the anti-apop-
totic protein bcl-2 [116] and the Rb protein, suppression
of p53 [117], and increasing numbers of newly formed
endothelial progenitor cells [118].
AA has been demonstrated to reduce endothelial cell
expression of the adhesion molecule ICAM-1 in
response to TNF-alpha in vitro in human umbilical vein
endothelial (HUVEC) cells (HUVEC) [119]. By reducing
adhesion molecule expression, AA suppresses systemic
neutrophil extravasation during sepsis, especially in the
lung [120]. Other endothelial effects of AA include
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inflammatory stimuli [121], and effect expected to pre-
vent the hypercoaguable state. Furthermore, ascorbate
supplementation has been directly implicated in sup-
pressing endothelial permeability in the face of inflam-
matory stimuli [122-124], which would hypothetically
reduce vascular leakage. Given the importance of NF-
kappa B signaling in coordinating endothelial inflamma-
tory changes [79-81], it is important to note that AA at
pharmacologically attainable concentrations has been
demonstrated to specifically inhibit this transcription
factor on endothelial cells [125]. Mechanistically, several
pathways of inhibition have been identified including
reduction of i-kappa B phosphorylation and subsequent
degradation [126], and suppression of activation of the
upstream p38 MAPK pathway [127]. In vivo data in sup-
port of eventual use in humanshas been reported show-
ing that administration of 1 g per day AA in
hypercholesterolemic pigs results in suppression of
endothelial NF-kappa B activity, as well as increased
eNOS, NO, and endothelial function [128]. In another
porcine study, renal stenosis was combined with a high
cholesterol diet to mimic renovascular disease. AA
administered i.v. resulted in suppression of NF-kappa B
activation in the endothelium, an effect associated with
improved vascular function [129].
An important factor in reports of clinical studies of
AA is the difference in effects seen when different
routes of administration are employed. Supplementation
with oral AA appears to have rather minor effects, per-
haps due to the rate-limiting uptake of transporters
found in the gut. Indeed, maximal absorption of AA
appears to be achieved with a single 200 mg dose [130].
Higher doses produce gut discomfort and diarrhea
because of effects of ascorbate accumulation in the
intestinal lumen [131]. This is why some studies use
parenteral administration. An example of the superior
biological activity of parenteral versus oral was seen in a
study administering AA to sedentary men. Parenteral
but not oral administration was capable of augmenting
endothelial responsiveness as assessed by a flow-
mediated dilation assay [132].
Cancer Patients are Deficient in Ascorbic Acid
The general activity of AA as an anti-oxidant implies
that conditions associated with chronic inflammation
and oxidative stress would lead to its depletion. As
reviewed by McGregor and Biesalski [133], numerous
inflammatory conditions including gastritis [134], dia-
betes [134,135], pancreatitis [136], pneumonia [137],
osteoporosis [138], rheumatoid arthritis [139], are all
associated with marked reduction in plasma AA levels
as compared to healthy controls. Within the context of
this discussion, profound reduction of AA is observed in
cancer patients [140-146], SIRS patients [147], and ICU
patients [134].
Some studies have demonstrated correlation between
plasma AA and survival. Mayland et al. [141] measured
plasma AA in 50 end-stage cancer patients in a hospice
setting. A correlation between deficiency in AA,
decreased survival, and higher expression of the inflam-
matory marker CRP was noted. More recently, a corre-
lation between tumor aggressiveness and low AA
content has been made [148]. Kuiper et al.f o u n dt h a t
the proangiogenic transcription factor HIF-1 alpha is
negatively correlated with tumor AA content. Correla-
tions where also made between low AA content, high
VEGF, and levels of the anti-apoptotic protein bcl-2.
Cancer patients are known to exhibit a general state of
chronic inflammation which, as stated above, is related
to the tumor itself and the interaction of host factors
with the tumor. Elevation in the level o f classical
inflammatory markers such as fibrinogen [149-155],
CRP [156-160], erythrocyte sedimentation rate [161],
ferritin [162-165], neopterin [166-168], homocysteine
[169,170], IL-6 [161,171], and free radical stress
[172-175] have been well-documented in cancer
patients, with numerous studies demonstrating that ele-
vation is associated with poor survival.
The possibility that inflammation itself reduces plasma
AA was shown by Fain et al. [176], who examined 184
hospitalized patients and observed that 47.3% suffered
from hypovitaminosis C as defined as either depletion (i.
e., serum AA levels < 5 mg/l) or deficiency (i.e., serum
AA levels < 2 mg/l). Interestingly, patients with an acti-
vated acute phase response, as defined by erythrocyte
sedimentation rate above 20 mm and an increase in
acute phase reactants (CRP >10 mg/l and/or fibrinogen
> 4 g/l) had lower serum AA levels. Also associated
with decreased serum AA levels was reduction in hemo-
globin and albumin. A Japanese population study of 778
men and 1404 women, aged 40-69 years, demonstrated
an e g a t i v ec o r r e l a t i o nb e t w e e np l a s m aA Ac o n t e n ta n d
CRP [177]. In an interventional study, Block et al. exam-
ined 396 healthy nonsmokers randomized to receive
either 1000 mg/day vitamin C, 800 IU/day vitamin E, or
placebo, for 2 months. A statistically significant decrease
in plasma CRP levels was found only in the group
receiving AA [178].
While a study by Mayland et al. demonstrated that, in
50 patients with advanced malignancies of various types,
a correlation between high CRP levels and AA defi-
ciency existed [179], to our knowledge no interventional
studies in cancer patients have been performed to assess
the capacity of AA administered i.v. to inhibit chronic
inflammation. In the absence of such studies, we looked
at reports of AA inhibition ofs inflammatory markers in
the context of other diseases to determine whether a
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supporting studies exist. Administration of IV AA has
been shown to decrease CRP levels in smokers [180].
Oral AA supplementation decreased CRP levels in a
trial of 44 patients suffering from atrial fibrillation after
cardioversion [181]. In a study of 12 healthy volunteers,
it was shown that i.v. AA inhibited endothelin-induced
IL-6 production [182]. In a study of 1463 coronary
artery disease patients, a negative correlation between
neopterin (a catabolic product of GTP indicative of
immune activation) and AA concentration was noted
[183]. Given that there are, at present, numerous trials
being conducted using i.v. AA in the treatment of can-
cer [26-31], it is highly unfortunate that none of them
are assessing inflammatory markers or other potential
mechanisms of action. This may, to some degree, be
detrimental to future study of AA in cancer treatment:
if poor tumor regression data is generated, replication of
these trials with inclusion of sensitive inflammatory
marker endpoints may never occur.
SIRS patients are deficient in AA
The progression of SIRS into MOF is perhaps one of the
most inflammation-driven disease pathologies. If the
overall hypothesis that AA is consumed by inflammation
is correct, these patients should be highly deficient. This
appears to be the case: several studies have demon-
strated severe deficiency in AA in patients with sepsis
and septic shock compared to healthy volunteers. Doise
et al. examined 37 patients with septic shock, 19
patients with severe sepsis, and 6 healthy volunteers
over the period of 10 days. A significant deficiency of
AA was observed compared to controls, and blood AA
levels continued to decline while the patients were in
the ICU. No difference between the deficiency in septic
shock and severe sepsis was noted [184]. The association
ofAA deficiency with poor outcomes was further
strengthened in a study of 16 ICU patients in which a
statistically significant decrease in AA was found in
patients progressing to MOF [185]. Indeed, septic
patients have been demonstrated to exhibit a much
higher rate of ascorbate consumption compared to
healthy volunteers, based on studies in which predefined
doses of AA were administered and in vivo degradation
and disappearance was assessed [186].
Animal models suggest a critical role for AA in pro-
tecting from/inhibiting the septic process. In an elegant
study, mice deficient for ascorbic acid synthesis (i.e.,
deficient in L-gulono-gamma-lactone oxidase) were
depleted of exogenous ascorbate by feeding on an ascor-
bate-free diet and challenge with the pathogen Klebsiella
pneumonia. Mortality was 3-fold higher in ascorbate-
deficient animals compared to controls, which received
a standard ascorbate-containing diet [187]. Given that
cancer patients are generally deficient in AA, these find-
ings may suggest the importance of maintaining at least
normal AA levels to prevent from onset of SIRS
[140-146]. Supplementation with AA has been demon-
strated to protect against sepsis-associated death. Using
a “feces injection into the peritoneum” model of sepsis,
i.v. injection of 10 mg/kg AA resulted in 50% survival,
in contrast to a 19% survival in animals receiving saline
[98]. Supplementation with AA improved outcome in
sepsis-associated hypoglycemia [188], microcirculatory
abnormalities [189], and blunted endothelial responsive-
ness [101,102,190] in animal models.
From a clinical perspective, Crimi et al.r e p o r t e da
prospective randomized study in which vitamins C (500
mg/d) and E (400 IU/d) where administered via enteral
tube to a group of 105 critically ill patients, whereas a
control group of 111 patients received a isocaloric for-
mula without supplementation with these vitamins. At
patient follow-up, reduced TBARS and isoprostanes
(markers of oxidative stress) were observed in the trea-
ted group. In addition, improved survival at 28 days of
treatment was reported: 54.3% in the antioxidant group
and 32.5% in the regular-feeding group (p < 0.05) [191].
Nathens et al. performed a larger study of 595 critically
ill surgical patients where the majority suffered from
trauma. AA and vitamin E where administered i.v. 3
times per day (1000 mg per injection and 1000 IU ent-
erally, respectively). Reductions in the time of hospital
stay, pulmonary mortality, and need for mechanical ven-
tilation was observed in the treated group. Furthermore,
MOF incidence was reduced in the anti-oxidant supple-
mented group [192]. In a study of the effect of AA
alone in treatment of burn patients with > 30% of their
total body surface area affected, patients were given AA
i.v. (66 mg/kg/hr for 24 hours, n = 19) or received only
standard care (controls, n = 18). AA treatment resulted
in statistically significant reductions in 24 hr total fluid
infusion volume, fluid retention (indicative of vascular
leakage), and MDA. Perhaps most striking was the
decrease in the need for mechanical ventilation: the
treated group required an average of 12.1 ± 8.8 days,
while the control group required 21.3 ± 15.6 days [193].
Thus it appears that cancer patients generally have a
deficiency in AA which may predispose to SIRS and
subsequent MOF, and patients with other diseases exhi-
bit symptom severity inversely associated with AA
levels. Patients who do develop SIRS and MOF have
even greater depletion of AA and, as a result, various
changes in the endothelium occur which exacerbate
progression to mortality. Thus, there is some rationale
for use of AA in cancer patients to prevent/treat SIRS.
There is an additional possible benefit in that AA may
actually inhibit cancer initiation and growth. Without
providing an exhaustive review of this controversial
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performed in this area.
AA Effects in Cancer
The state of AA deficiency in cancer patients, whether
or not as a result of inflammation, suggests that supple-
mentation may yield benefit in quality of life. Indeed,
this was one of the main findings that stimulated us to
write this review [12]. Improvements in quality of life
were also noted in the early studies of Murata et al. [15]
and Cameron [11]. But, in addition to this endpoint,
there appears to be a growing number of studies sug-
gesting direct anti-cancer effects via generation of free
radicals locally at tumor sites [21]. In vitro studies on a
variety of cancer cells including neuroblastoma [194],
bladder cancer [195], pancreatic cancer [196], mesothe-
lioma [197], and hepatoma [198], have demonstrated
cytotoxic effects at pharmacologically-achievable con-
centrations. Enhancement of cytotoxicity of docetaxel,
epirubicin, irinotecan, and 5-FU to a battery of tumor
cell lines by AA was demonstrated in vitro [199]. In vivo
studies have also supported the potential anticancer
effects of AA. For example, Pollard et al.u s e dt h er a t
PAIII androgen-independent syngeneic prostate cancer
cell line to induce tumors in Lobund-Wistar rats. Daily
intraperitoneal administration of AA for 30 days (with
evaluation at day 40) revealed significant inhibition of
tumor growth and reduction in pulmonary and lympha-
tic metastasis [200]. Levine’s group reported successful
in vivo inhibition of human xenografted glioma, overian,
and neuroblastoma cells in immune-deficient animals by
administration of AA. Interestingly, control fibroblasts
were not affected [23]. Clinical reports of remission
induced by i.v. AA have been published [201]. However,
as mentioned above, formal trials are still ongoing.
Table 1 summarizes previous trials.
In addition to direct cytotoxicity of AA on tumor
cells, inhibition of angiogenesis may be another mechan-
ism of action. It has been reported that AA inhibits
HUVEC proliferation in vitro [202] and suppresses neo-
vascularization in the chorionic allontoic membrane
a s s a y[ 2 0 3 ] .W er e c e n t l yr e p o r t e dt h a tin vivo adminis-
tration of AA suppresses vascular cord formation in
mouse models [204]. Supporting this, Yeom et al.
demonstrated that parenteral administration of AA in
the S-180 sarcoma cell model leads to reduced tumor
growth, which was associated with suppression of angio-
genesis and reduced expression of the pro-angiogenic
factors bFGF, VEGF, and MMP-2 [205]. Recent studies
suggest that AA suppresses activation of the hypoxia-
inducible factor (HIF)-1, which is a critical transcription
factor that stimulates tumor angiogenesis [206-208]. The
clinical relevance of this has been demonstrated in a
study showing that endometrial cancer patients with
reduced tumor ascorbate levels have higher levels of
active HIF-1 and a more aggressive phenotype [148].
Thus the possibility exists that administration of AA
for treatment of tumor inflammation-mediated patholo-
gies may also cause an antitumor effect. Whether this
effect is mediated by direct tumor cytotoxicity or inhibi-
tion of angiogenesis remains to be determined. Unfortu-
nately, none of the ongoing trials of AA in cancer
patients seek to address this issue [26-31].
Areas needing study: AA and Immunity
Despite numerous claims in the popular media (and
even on labels on over-the-counter vitamin packaging),
AA stimulation of immune function to reduce tumor
initiation and growth is not clear-cut. This is partly
because ROS are involved in numerous signaling events
in immune cells [209]. For example, it is known that T
cell receptor signaling induces an intracellular flux of
ROS which is necessary for T cell activation [210].
There are also numerous studies demonstrating that
ascorbic acid, under certain conditions, can actually
inhibit immunity. For example, high dose ascorbate inhi-
bits T cell and B cell proliferative responses as well as
IL-2 secretion in vitro [211,212], and NK cytotoxic activ-
ity [213]. In addition, AA has been demonstrated to
inhibit T cell activation of dendritic cells by encouraging
them to remain in an immature state, in part through
inhibition of NF-kappa B [214].
It is possible, although not formally tested, that the
immune stimulatory effects of AA are actually observed
in the context of background immune suppression or in
situations of AA deficiency, both of which are well-
known in the cancer and SIRS patient. Cleavage of the
T cell receptor (TCR) zeta chain is a common occur-
rence in cancer [215-219] and SIRS patients [220,221].
The zeta chain is an important functional factor in T
cell and NK cell activation, and is the most highly
expressed of the immunoreceptor tyrosine-based activa-
tion motifs (ITAMs) on T and NK cells [222]. At the
cellular level, cleavage of the zeta chain is associated
with loss of T/NK cell function and spontaneous apop-
tosis [223-225] and, in the clinic, it is associated with
poor prognosis [226-231].
Since loss of the TCR zeta chain is found in other
inflammatory conditions ranging from hemodialysis
[232,233], to autoimmunity [234-237], to heart disease
[238], the possibility that inflammatory mediators such as
ROS cause TCR zeta downregulation has been suggested.
Circumstantial evidence comes from studies correlating
presence of inflammatory cells such as tumor-associated
macrophages with suppression of zeta chain expression
[239]. Myeloid suppressor cells (which are known to pro-
duce high concentrations of ROS [240-242]) have also
been demonstrated to induce reduction of TCR zeta chain
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anti-oxidants has been shown to reverse TCR zeta chain
cleavage in tissue culture [245,246]. Therefore, from the T
cell side of immunity, an argument could be made that
intravenous ascorbic acid may upregulate immunity by
blocking zeta chain downregulation in the context of can-
cer and acute inflammation.
While it is known that AA functions as an antioxidant
in numerous biological conditions, as well as reduces
inflammatory markers, the possibility that AA actually
increases immune function in cancer patients has never
been formally tested. This is an area that in our opinion
cries out for further studies.
Conclusion
AA administered intravenously has a long and contro-
versial history in relation to reducing tumors in patients.
This has impeded research into other potential benefits
of this therapy in cancer patients such as reduction of
inflammation, improvement of quality of life, and reduc-
tion ofSIRS initiation and progression to MOF. While
ongoing clinical trials of i.v. AA for cancer may or may
not meet the bar to grant this modality a place amongst
the recognized chemotherapeutic agents, it is critical
that we collect as much biological data as possible,
given the possibility of this agent to be a wonderful
adjuvant therapy.
Acknowledgements
This work was supported by Allan P Markin. The paper is dedicated to
Florica Batu Ichim, who passed away September 4
th, 2010 after a 23 year
battle with leukemia, and to Drs Jeffrey Lipton, Hans Messner, Mark Minden
and the Team at Princess Margaret Hospital who cared for her for over two
decades.
Table 1 Ascorbic Acid Cancer Trials
Condition Number of Patients Dose/Route Finding Ref
Mixture of solid
tumors at
different stages
49 Intravenous for 10 days 10 g and
subsequently daily oral 10 g/day
17 pts no response, 10 pts minimal response,
11 pts growth retardation, 2 pts cytostasis, 5 pts
tumor regression, 4 pts tumor hemorrhage/
necrosis
11
Terminal cancer
patients
39 Intravenous 10 g vitamin C twice
with a 3-day interval and an oral
intake of 4 g vitamin C daily for a
week
Health score improved from 36+/-18 to 55+/-16
(p = 0.001). Significantly higher scores for
physical, role, emotional, and cognitive function
(p < 0.05). In symptom scale, the patients
reported significantly lower scores for fatigue,
nausea/vomiting, pain, and appetite loss
(p < 0.005).
12
Terminal cancer
patients
100 cancer pts treated as compared
to 1000 controls. 50 of the treated pts
were in the publication described in
ref 11.
Intravenous for 10 days 10 g and
subsequently daily oral 10 g/day
Mean survival time > 4.2 times as great for the
ascorbate subjects (more than 210 days) as for
the controls (50 days). Survival-time curves
indicate that deaths occur for about 90% of the
ascorbate-treated patients at one-third the rate
for the controls and that the other 10% have a
much greater survival time, averaging more
than 20 times that for the controls.
13
Terminal cancer
patients
99 in one hospital and 31 in another
hospital
30g/day intravenously Hospital #1: Survival of 43 days for 44 low-
ascorbate patients and 246 days for 55 high-
ascorbate patients.
Hospital #2: 48 days for 19 control patients and
115 days for 6 high-ascorbate patients.
15
Terminal cancer
patients
60 AA, 63 placebo controlled 10 g/day oral The two groups showed no appreciable
difference in changes in symptoms,
performance status, appetite or weight. The
median survival for all patients was about seven
weeks, and the survival curves essentially
overlapped.
16
Advanced
colorectal
cancer
50 AA, 50 control 10 g/day oral AA treatment had advantage over placebo with
regard to either the interval between the
beginning of treatment and disease progression
or patient survival. Among patients with
measurable disease, none had objective
improvement.
17
Renal
metastatic, B
cell lymphoma,
Bladder cancer
3 Cases 50-100 g intravenously, various
regimens
Tumor regression and unexpectedly long
survival.
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